Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7581853 | 1.00 | CA1 (0.58) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL4668694 | 1.00 | CA1 (0.58) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL8114468 | 1.00 | CA1 (0.58) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL4842363 | 0.92 | CA1 (0.64) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL4836421 | 0.92 | CA1 (0.64) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL4836414 | 0.92 | CA1 (0.64) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL9466787 | 0.86 | CA1 (0.54) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL2216473 | 0.83 | CA1 (0.50) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL2340083 | 0.82 | CA1 (0.51) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL6482663 | 0.82 | CA1 (0.51) | CA1CA2CA7CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149769-A1 | NOVEL CARBONYL REDUCTASE, GENE THEREFOR AND USE THEREOF | KANEKA CORPORATION (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20090029430-A1 | Novel Carbonyl Reductase, Gene Therefor and Use Thereof | KANEKA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1811021-A1 | NOVEL CARBONYL REDUCTASE, GENE THEREFOR AND USE THEREOF | Kaneka Corporation (JP) | 2007-07-25 | — | — | EP | disclosed |
| WO-2002096915-A1 | PROCESS FOR PRODUCING OPTICALLY PURE Δ - HYDROXY-Β -KETOESTER DERIVATIVES | SAMSUNG FINE CHEMICALS CO., LTD. (KR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029430-A1 | Novel Carbonyl Reductase, Gene Therefor and Use Thereof | AKR1C4, CBR3, FAR1 | CA1 3006/4885CA2 3454/4885CA7 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.